Imagine a 3D printer that creates a custom-fit 'smart bandage' for wounds that won't heal, like those from diabetes. This bandage doesn't just cover the wound; it releases medicine in tiny bubbles and can actually shrink using light to pull the edges of the skin together. It acts like a temporary biological bridge that helps the body regrow skin, nerves, and blood vessels.
Chronic wounds caused by diabetes and obesity create a massive socioeconomic burden because current treatments fail to reliably regenerate skin. There is a critical need for dressings that provide both mechanical stability and active biological healing.
A 3D-printable biological scaffold containing drug-loaded nanocapsules, elastin-like polypeptides, and a UV-activated contractile mechanism, supported by custom bioprinting software.
If you are a bioprinting company dealing with a lack of clinical applications for 3D trajectory software — this project developed a customized 3D bioprinter and software that strategically places biological compounds to treat chronic wounds.
If you are a pharma company dealing with unstable drug release in wound care — this project developed hyaluronic acid-based nanocapsules for antibiotics and anti-inflammatories that show stability over a month.
If you are a clinic dealing with the high economic burden of chronic wound management — this project developed a pro-regenerative matrix that uses UV light to induce contractile force for faster wound closure.
Based on available project data, specific pricing is not mentioned, but the project aims to define a business model to decrease the economic burden of wound care management.
The project utilizes 3D bioprinting and a customized trajectory software to allow for patient-tailored dressings, though industrial scaling details are not yet specified.
Based on available project data, the project is currently defining a regulatory framework and a viable exploitation strategy to ensure translation to clinical practice.
Health professionals are guiding the development to ensure the dressing can be used effectively by medical staff in clinical settings.
The project period runs from 2023-01-01 to 2026-12-31, suggesting a transition toward clinical application by the end of 2026.
The consortium is well-balanced for commercial translation, featuring 18 partners across 8 countries. With a 39% industry ratio (7 industrial partners, 8 of which are SMEs), there is a strong focus on market viability. The mix of 4 universities and 7 research centers ensures a deep technical pipeline for the 3D bioprinting and biomaterial components.
Contact FUNDACION CIDETEC in Spain for licensing and partnership inquiries.
Contact us to connect with the FORCE REPAIR consortium for early adoption of 3D-printed wound care.
